Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,710 total articles
Castle Biosciences President and CEO Derek J. Maetzold sold a total of 19,300 shares of company common stock on March 17 and 18, 2026, in transactions filed on a Form 4. The trades, executed under a Rule 10b5-1 plan adopted in December 2025, generated $500,098 in proceeds. The company recently posted quarterly results that beat expectations on both…
Barry Ticho, chief medical officer at Stoke Therapeutics (STOK), sold 13,147 shares of common stock across March 17-19, 2026, generating about $413,019. The sales were conducted at prices between $31.2838 and $33.3754 per share and were reported on a Form 4 filing. Ticho also exercised options to purchase 1,365 shares at $2.19 on March 19. The tran…
Sarah Blake, SVP and Chief Accounting Officer at Venture Global, sold 200,000 Class A shares for $3.2 million on March 19, 2026, and concurrently exercised 200,000 options. The company reported a Q4 2025 EPS shortfall despite strong revenue growth and announced major project financing; analysts have adjusted price targets while an InvestingPro note…
Global Partners LP Chief Operating Officer Mark Romaine sold 2,223 common units of the partnership in two transactions on March 12 and March 13, 2026, totaling $105,751. The company reported mixed fourth-quarter 2025 results across its segments, and an analyst at Stifel raised the price target to $46 while keeping a Hold rating. InvestingPro data c…
Venture Global Chief Financial Officer Jonathan W. Thayer completed $50.5 million in Class A share sales and exercised more than 2.6 million options in mid-March 2026, while also receiving a new option grant. The transactions occurred as the stock trades well above the company’s assessed Fair Value by InvestingPro and after Venture Global reported …
Zscaler, Inc. Chief Product Officer Adam Geller sold 3,579 shares of company stock across two transactions on March 17 and 18, 2026, raising $554,031. One sale covered tax withholding from vested restricted stock units; the other was executed under a Rule 10b5-1 plan adopted in March 2025. The transactions leave Geller with 46,949 shares. The sales…
Keith D. Larson, General Counsel and Secretary of Venture Global, completed significant Class A Common Stock sales totaling roughly $76.8 million on March 18 and 19, 2026, while also acquiring shares by exercising options and receiving a new option grant. The insider moves coincide with a sharp year-to-date share price rise and come after a quarter…
Noble Corp plc Executive Vice President and CFO Richard B. Barker sold 150,000 A Ordinary Shares on March 18, 2026, generating roughly $6.9 million in proceeds through two transactions executed under a Rule 10b5-1 plan. The sale occurred while the stock sits close to its 52-week peak and after the company posted mixed fourth-quarter 2025 results an…
Noble Corp PLC President and CEO Robert W. Eifler sold 100,000 company shares on March 18, 2026, for $4.6 million in two tranches executed under a Rule 10b5-1 plan. The company posted mixed fourth-quarter 2025 results, with an EPS shortfall against expectations but revenue above forecasts. External analysis flags the stock as overvalued relative to…
Deborah Stein, a director at RB Global INC (NYSE: RBA), bought 400 shares on March 18, 2026, for $98.74 each, a total outlay of $39,496. The transaction raised her direct holdings to 1,400 shares. The purchase price exceeded the prevailing share price of $95.84, while InvestingPro’s Fair Value assessment indicates the stock remains undervalued. Sep…
Stoke Therapeutics Chief Financial Officer Thomas Leggett sold 5,378 shares of company stock on March 17 and 18, 2026, in a series of transactions that generated $147,144. The disposition was reported as an issuer-mandated sale to satisfy tax withholding tied to vested restricted stock units. The trades come amid mixed signals for the company: stro…
Paul A. Maleh, president and CEO of CRA International, sold 7,182 shares on March 17, 2026, for a total of $1.16 million under a Rule 10b5-1 trading plan. The company reported record revenue for the fourth quarter and full year of 2025, topping revenue estimates but narrowly missing EPS forecasts. CRAI shares traded near their 52-week low amid thos…
Jason Hoitt, chief patient officer at Stoke Therapeutics (NASDAQ: STOK), sold 3,712 shares of common stock on March 17-18, 2026 to satisfy tax withholding obligations tied to restricted stock unit vesting. The transactions totaled $119,310 and leave Hoitt with 10,276 shares. The company also disclosed executive compensation details and updated clin…
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, sold 8,995 shares of company stock across transactions on March 17 and 18, 2026, generating approximately $285,900. The sales were disclosed as mandated transactions to satisfy tax withholding tied to restricted stock unit vesting and settlement. Separately, Stoke's boar…
ServiceTitan Chief Executive Officer Ara Mahdessian sold $159,874 of Class A Common Stock in multiple transactions on March 18, 2026, and converted 2,289 Class B shares into Class A stock. The stock has faced notable declines recently even as the company posted better-than-expected fourth-quarter results and analysts adjusted earnings and price tar…
Medpace Holdings President Jesse J. Geiger sold 31,707 shares on March 17, 2026, generating roughly $14.44 million. The transaction accompanied an exercise of options for the same number of shares at $138.87, which vested on February 15, 2026. Recent analyst activity has reflected evolving sentiment on Medpace's valuation and market position.
Enliven Therapeutics Chief Medical Officer Helen Louise Collins sold 5,000 shares on March 17, 2026, and exercised options to acquire 5,000 additional shares the same day. The stock has risen since the sale and Enliven reported positive initial Phase 1b results for ELVN-001 in chronic myeloid leukemia, while also appointing Scott Garland to its boa…
Andrew H. Rubenstein, CEO and President of Accel Entertainment, sold 3,938 shares of Class A-1 Common Stock on March 17, 2026, for roughly $44,223. The transaction occurred as the company reported robust fourth-quarter 2025 results and as an analyst firm raised its price target while maintaining a Market Outperform rating. Valuation metrics cited i…
Alaleh Nouri, Executive Vice President and CLO at PROCEPT BioRobotics Corp, sold 5,363 shares of company stock on March 19, 2026, for approximately $139,230 under a Rule 10b5-1 trading plan. The transaction occurred while shares trade at $25.68, down 56% over the past year. The company recently launched its HYDROS Robotic System in the U.K., added …
ServiceTitan, Inc. (TTAN) reported that Director and President Vahe Kuzoyan sold 3,221 shares of Class A common stock on March 18, 2026, for a total of $224,984. The trades were executed at an average price of $69.86, with individual transactions ranging from $68.33 to $74.16. On the same day Kuzoyan converted an equal number of Class B shares into…
Leonard M. Tannenbaum, a director and ten percent owner of Advanced Flower Capital Inc. (NASDAQ:AFCG), bought 151,200 shares of the company's common stock in two transactions on March 18 and March 19, 2026, at $2.59 per share for a total of $391608. The purchases leave him with more than 6.19 million shares directly and additional indirect holdings…
Richard Page Howard, a trustee of North European Oil Royalty Trust (NRT), sold 25,000 units of the trust on March 17, 2026 in two separate trades that together generated $215,601. After the sales, Howard retains direct ownership of 250,000 units. The trust currently yields 9.02% and, according to analysis cited, remains undervalued relative to its …
ServiceTitan Chief Financial Officer Sherry David sold 17,777.5 shares of Class A common stock on March 18, 2026, generating $1.24 million at an average trade price of $69.86 per share. The disposal, executed across several price tranches, was made to meet tax obligations arising from restricted stock unit vesting. The company recently reported bet…
Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, sold 3,261 shares on March 17, 2026 under a Rule 10b5-1 plan, realizing $74,416. The company recently reported fourth-quarter 2025 results that missed consensus on both EPS and revenue and is contending with an activist campaign from a holder of roughly 7.3% of shares.
Director Mark Froimson sold 500 shares of Pacira BioSciences Inc. (NASDAQ: PCRX) on March 17, 2026, in a Form 4 filing. The trade, at $21.81 per share for $10,905, leaves Froimson with 20,136 shares. Pacira reported fourth-quarter 2025 results that missed EPS and revenue expectations, and activist investor DOMA Perpetual Capital Management LLC has …
